JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB201527

Alexa Fluor® 488 Anti-HLA-DPB1 抗体 [EPR11226]

Alexa Fluor® 488 Anti-HLA-DPB1 antibody [EPR11226]

Be the first to review this product! Submit a review

|

(3 Publications)

Rabbit Recombinant Monoclonal HLA-DPB1 antibody - conjugated to Alexa Fluor® 488. Suitable for ICC/IF, IHC-P and reacts with Human samples. Cited in 3 publications.

別名を表示する

HLA-DP1B, HLA-DPB1, MHC class II antigen DPB1

1 Images
Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 488 Anti-HLA-DPB1 antibody [EPR11226] (AB201527)
  • ICC/IF

Lab

Immunocytochemistry/ Immunofluorescence - Alexa Fluor® 488 Anti-HLA-DPB1 antibody [EPR11226] (AB201527)

ab201527 staining HLA-DPB1 in HDLM-2 (human Hodgkin lymphoma cell) cells at 1/100 dilution (5 μg/ml). The cells were fixed with 80% Methanol, and permeabilized with 0.1% PBS-Triton X-100. Positive staining in HDLM-2 cell line (shown in green) and negative staining in HEK-293 cell line. The counterstain, ab195889 Alexa Fluor® 594 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker at 1/200 (2.5 μg/ml) was observed in magenta. Nuclear DNA was labelled with DAPI (shown in blue).

Image was taken with a confocal microscope.

Negative control : HEK-293

関連する標識済み抗体及び組成の異なる製品 (5)

Key facts

宿主種

Rabbit

クローン性

Monoclonal

クローン番号

EPR11226

アイソタイプ

IgG

標識

Alexa Fluor® 488

励起波長/蛍光波長

Ex: 495nm, Em: 519nm

キャリアフリー

No

交差種

Human, Human

アプリケーション

ICC/IF, IHC-P

applications

免疫原

The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "ICCIF-species-checked": "testedAndGuaranteed", "ICCIF-species-dilution-info": "1/100", "ICCIF-species-notes": "<p>This product gave a positive signal in Jurkat cells fixed with 100% methanol (5 min).</p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>" } } }

製品の詳細

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Alexa Fluor® is a registered trademark of Molecular Probes, Inc, a Thermo Fisher Scientific Company. The Alexa Fluor® dye included in this product is provided under an intellectual property license from Life Technologies Corporation. As this product contains the Alexa Fluor® dye, the purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). As this product contains the Alexa Fluor® dye the sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: in manufacturing; (ii) to provide a service, information, or data in return for payment (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are sold for use in research. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, 5781 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@thermofisher.com.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 7.4 Preservative: 0.02% Sodium azide Constituents: PBS, 30% Glycerol (glycerin, glycerine), 0.05% BSA
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle|Store in the dark

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.
See full target information HLA-DPB1

文献 (3)

Recent publications for all applications. Explore the full list and refine your search

Indian journal of urology : IJU : journal of the Urological Society of India 39:223-227 PubMed37575160

2023

EphrinB2: Expression of a novel potential target in renal cell carcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Chhavi Gupta,Akash Pramod Sali,Alexandra Jackovich,Binyun Ma,Sarmad Sadeghi,David Quinn,Parkash Gill,Inderbir Gill

Cancer cell 41:871-886.e10 PubMed37059105

2023

Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma.

Applications

Unspecified application

Species

Unspecified reactive species

Giorgio Gaglia,Megan L Burger,Cecily C Ritch,Danae Rammos,Yang Dai,Grace E Crossland,Sara Z Tavana,Simon Warchol,Alex M Jaeger,Santiago Naranjo,Shannon Coy,Ajit J Nirmal,Robert Krueger,Jia-Ren Lin,Hanspeter Pfister,Peter K Sorger,Tyler Jacks,Sandro Santagata

Cell 184:4753-4771.e27 PubMed34388391

2021

Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.

Applications

Unspecified application

Species

Unspecified reactive species

Kazuhiro Koikawa,Shin Kibe,Futoshi Suizu,Nobufumi Sekino,Nami Kim,Theresa D Manz,Benika J Pinch,Dipikaa Akshinthala,Ana Verma,Giorgio Gaglia,Yutaka Nezu,Shizhong Ke,Chenxi Qiu,Kenoki Ohuchida,Yoshinao Oda,Tae Ho Lee,Babara Wegiel,John G Clohessy,Nir London,Sandro Santagata,Gerburg M Wulf,Manuel Hidalgo,Senthil K Muthuswamy,Masafumi Nakamura,Nathanael S Gray,Xiao Zhen Zhou,Kun Ping Lu
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com